Creative Medical Technology Holdings Reports Q2 2026 Financial Results with Increased Losses and No Revenue

Creative Medical Technology Holdings, Inc. (CMTH) reported its financial results for the second quarter of 2026, revealing a continued trend of operating losses and no revenue generation. For the three months ended June 30, 2026, the company recorded a net loss of $1.51 million, compared to a net loss of $1.23 million for the same period in 2025. The operating loss for the quarter was $1.56 million, an increase from the $1.26 million loss reported in the prior year. The company has not generated any revenue during the first half of 2026, a decline from the $3,000 reported in the first half of 2025.

Total operating expenses for the second quarter of 2026 amounted to $1.56 million, up from $1.26 million in the same quarter of the previous year. This increase was primarily driven by a 48% rise in selling, general, and administrative expenses, which totaled $1.08 million, largely due to a nationwide marketing campaign and increased staffing costs. Research and development expenses decreased to $459,200 from $501,261, reflecting a shift in focus as the company progresses through clinical trial phases.

As of June 30, 2026, CMTH reported total assets of $9.38 million, an increase from $7.81 million at the end of 2025. The company’s cash position improved to $8.71 million, up from $7.21 million at the end of the previous fiscal year. This increase was bolstered by financing activities that generated $4.48 million, primarily from warrant exercises. The company’s total stockholders' equity also rose to $8.68 million, compared to $7.52 million at the end of 2025.

Strategically, CMTH is advancing its clinical programs, including the CELZ 201 (Olastrocel™) trial for chronic lower back pain, which has received FDA Fast Track designation. The company is also exploring additional therapeutic areas, including immunotherapy and regenerative medicine, through its proprietary platforms. Despite the lack of revenue, CMTH continues to invest in research and development, with a focus on expanding its clinical trials and enhancing its product offerings.

Looking ahead, CMTH remains focused on its clinical development pipeline and aims to secure partnerships to support its growth. The company acknowledges the challenges posed by its limited operating history and the competitive landscape in the biotechnology sector. Management is committed to optimizing resource allocation to enhance financial performance and drive future growth, while navigating the uncertainties of market conditions and regulatory environments.